[go: up one dir, main page]

PE20130496A1 - Tratamiento de artritis por lupus usando laquinimod - Google Patents

Tratamiento de artritis por lupus usando laquinimod

Info

Publication number
PE20130496A1
PE20130496A1 PE2012001382A PE2012001382A PE20130496A1 PE 20130496 A1 PE20130496 A1 PE 20130496A1 PE 2012001382 A PE2012001382 A PE 2012001382A PE 2012001382 A PE2012001382 A PE 2012001382A PE 20130496 A1 PE20130496 A1 PE 20130496A1
Authority
PE
Peru
Prior art keywords
laquinimod
lupus arthritis
arthritis treatment
treatment
active lupus
Prior art date
Application number
PE2012001382A
Other languages
English (en)
Inventor
Asi Haviv
Nora Tarcic
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44531530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130496(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of PE20130496A1 publication Critical patent/PE20130496A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE REFIERE A UN METODO DE TRATAMIENTO DE ARTRITIS POR LUPUS ACTIVO CON LAQUINIMOD QUE CONSISTE EN ADMINISTRAR PERIODICAMENTE POR AL MENOS 12 SEMANAS UNA CANTIDAD DE 0.5-1.0 mg/dia DE LAQUINIMOD SODICO EN FORMA ORAL, CONJUNTAMENTE CON CORTICOIDES, INMUNOSUPRESORES, FARMACOS ANTIPALUDICOS, ENTRE OTROS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHO METODO REDUCE LOS SINTOMAS DE ARTRITIS POR LUPUS ACTIVO COMO HINCHAZON DE ARTICULACIONES.
PE2012001382A 2010-03-03 2011-03-02 Tratamiento de artritis por lupus usando laquinimod PE20130496A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33935510P 2010-03-03 2010-03-03

Publications (1)

Publication Number Publication Date
PE20130496A1 true PE20130496A1 (es) 2013-05-08

Family

ID=44531530

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012001382A PE20130496A1 (es) 2010-03-03 2011-03-02 Tratamiento de artritis por lupus usando laquinimod

Country Status (21)

Country Link
US (4) US20110217295A1 (es)
EP (1) EP2542080B1 (es)
JP (2) JP2013521305A (es)
KR (1) KR20130036217A (es)
CN (1) CN102781239B (es)
AU (1) AU2011223702B2 (es)
BR (1) BR112012022064A2 (es)
CA (1) CA2791711A1 (es)
CL (1) CL2012002422A1 (es)
CO (1) CO6630086A2 (es)
EA (1) EA201290859A1 (es)
ES (1) ES2601819T3 (es)
MX (1) MX342001B (es)
NZ (1) NZ602512A (es)
PE (1) PE20130496A1 (es)
PH (1) PH12012501741A1 (es)
PL (1) PL2542080T3 (es)
PT (1) PT2542080T (es)
SG (2) SG183515A1 (es)
WO (1) WO2011109536A1 (es)
ZA (1) ZA201207125B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1937642T3 (pl) * 2005-10-19 2015-02-27 Teva Pharma Kryształy lakwinimodu sodu i proces ich wytwarzania
KR20140091778A (ko) 2006-06-12 2014-07-22 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
PL2234485T3 (pl) 2007-12-20 2014-06-30 Teva Pharma Stabilne preparaty lakwinimodu
ES2633658T3 (es) * 2008-09-03 2017-09-22 Teva Pharmaceutical Industries Ltd. Moduladores 2-oxo-1,2-dihidro-quinolina de la función inmunitaria
HRP20150988T1 (hr) * 2009-06-19 2015-11-20 Teva Pharmaceutical Industries Ltd. Lijeäśenje multiple skleroze lakvinimodom
BR112012002124A2 (pt) * 2009-07-30 2015-09-15 Teva Pharma tratamento da doença de crohn com laquinimode.
HRP20160997T1 (hr) 2009-08-10 2016-10-07 Teva Pharmaceutical Industries Ltd. Liječenje poremećaja povezanih s bdnf primjenom lakvinimoda
SG10201501535UA (en) * 2010-03-03 2015-04-29 Teva Pharma Treatment of lupus nephritis using laquinimod
DK2542079T3 (da) * 2010-03-03 2014-08-25 Teva Pharma Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat
EP2542080B1 (en) * 2010-03-03 2016-08-31 Teva Pharmaceutical Industries Ltd. Treatment of lupus arthritis using laquinimod
WO2012006538A1 (en) 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
WO2013055907A1 (en) 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
SG11201404214QA (en) 2012-02-03 2014-08-28 Teva Pharma USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
KR20140138725A (ko) 2012-02-16 2014-12-04 테바 파마슈티컬 인더스트리즈 리미티드 N-에틸-n-페닐-1,2-디하이드로-4,5-디-하이드록시-1-메틸-2-옥소-3-퀴놀린카복사미드, 그의 제조 및 용도
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
HK1215210A1 (zh) 2012-11-07 2016-08-19 Teva Pharmaceutical Industries Ltd. 拉喹莫德胺盐
NZ630427A (en) 2013-03-14 2017-06-30 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof
WO2014152009A1 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Transdermal formulations of laquinimod
HK1231413A1 (zh) 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340735A1 (fr) * 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US5912349A (en) * 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US6696407B1 (en) * 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
CN100390148C (zh) * 1999-10-25 2008-05-28 活跃生物技术有限公司 用于治疗恶性肿瘤的药物
US6852323B2 (en) * 2000-07-21 2005-02-08 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US6307050B1 (en) * 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
US6875869B2 (en) * 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US20070292461A1 (en) * 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
TW200509930A (en) * 2003-06-25 2005-03-16 Elan Pharm Inc Methods and compositions for treating rheumatoid arthritis
US8795693B2 (en) * 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
EP1763361A2 (en) * 2004-04-01 2007-03-21 Elan Pharmaceuticals, Inc. Steroid sparing agents and their use
US20090048181A1 (en) * 2004-09-02 2009-02-19 Schipper Hyman M Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
KR20080074120A (ko) * 2005-10-13 2008-08-12 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
PL1937642T3 (pl) * 2005-10-19 2015-02-27 Teva Pharma Kryształy lakwinimodu sodu i proces ich wytwarzania
WO2007048788A1 (en) * 2005-10-26 2007-05-03 Laboratoires Serono S.A. Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
US20080108641A1 (en) * 2006-02-08 2008-05-08 Ajami Alfred M Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
US8367629B2 (en) * 2006-02-14 2013-02-05 Noxxon Pharma Ag MCP-1 binding nucleic acids and use thereof
EP2007392A4 (en) * 2006-02-28 2010-04-07 Elan Pharm Inc METHOD FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES WITH ALPHA-4-INHIBITABLE COMPOUNDS
LT2676967T (lt) * 2006-02-28 2019-09-10 Biogen Ma Inc. Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu
ES2663377T3 (es) * 2006-03-03 2018-04-12 Biogen Ma Inc. Métodos para el tratamiento de enfermedades inflamatorias y autoinmunes con natalizumab
WO2007120656A2 (en) * 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
WO2007139887A2 (en) * 2006-05-22 2007-12-06 Cargill, Incorporated Methods for treating bone or joint inflammation
KR20140091778A (ko) * 2006-06-12 2014-07-22 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
WO2007146331A1 (en) * 2006-06-12 2007-12-21 Teva Pharmaceutical Industries, Ltd. Tannate salt form of polypeptide mixtures, their preparation and use
US20080090897A1 (en) * 2006-08-11 2008-04-17 The Johns Hopkins University Compositions and methods for neuroprotectin
ES2402175T3 (es) * 2007-07-11 2013-04-29 Medicinova, Inc. Tratamiento de una enfermedad neurodegenerativa progresiva con ibudilast
PL2234485T3 (pl) * 2007-12-20 2014-06-30 Teva Pharma Stabilne preparaty lakwinimodu
ES2633658T3 (es) * 2008-09-03 2017-09-22 Teva Pharmaceutical Industries Ltd. Moduladores 2-oxo-1,2-dihidro-quinolina de la función inmunitaria
HRP20150988T1 (hr) * 2009-06-19 2015-11-20 Teva Pharmaceutical Industries Ltd. Lijeäśenje multiple skleroze lakvinimodom
BR112012002124A2 (pt) * 2009-07-30 2015-09-15 Teva Pharma tratamento da doença de crohn com laquinimode.
HRP20160997T1 (hr) * 2009-08-10 2016-10-07 Teva Pharmaceutical Industries Ltd. Liječenje poremećaja povezanih s bdnf primjenom lakvinimoda
EP2542080B1 (en) * 2010-03-03 2016-08-31 Teva Pharmaceutical Industries Ltd. Treatment of lupus arthritis using laquinimod
WO2012006538A1 (en) * 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
NZ630427A (en) * 2013-03-14 2017-06-30 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof

Also Published As

Publication number Publication date
US20110217295A1 (en) 2011-09-08
US20130184310A1 (en) 2013-07-18
ZA201207125B (en) 2014-06-25
ES2601819T3 (es) 2017-02-16
EA201290859A1 (ru) 2013-04-30
US20160213663A1 (en) 2016-07-28
PL2542080T3 (pl) 2017-02-28
AU2011223702B2 (en) 2016-07-14
PH12012501741A1 (en) 2012-11-12
US20150086549A1 (en) 2015-03-26
BR112012022064A2 (pt) 2015-09-08
WO2011109536A1 (en) 2011-09-09
CN102781239B (zh) 2015-01-21
PT2542080T (pt) 2016-11-16
JP2013521305A (ja) 2013-06-10
SG183515A1 (en) 2012-10-30
MX2012010071A (es) 2012-10-03
CL2012002422A1 (es) 2012-12-21
CN102781239A (zh) 2012-11-14
CO6630086A2 (es) 2013-03-01
AU2011223702A1 (en) 2012-10-25
EP2542080B1 (en) 2016-08-31
CA2791711A1 (en) 2011-09-09
HK1177876A1 (zh) 2013-08-30
MX342001B (es) 2016-09-09
JP2016196473A (ja) 2016-11-24
EP2542080A1 (en) 2013-01-09
KR20130036217A (ko) 2013-04-11
NZ602512A (en) 2014-07-25
SG10201501539SA (en) 2015-04-29
EP2542080A4 (en) 2013-07-17

Similar Documents

Publication Publication Date Title
PE20130496A1 (es) Tratamiento de artritis por lupus usando laquinimod
PE20130690A1 (es) Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
EA201690107A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
MX2013002422A (es) Sales de lorcaserina con acidos opticamente activos.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
PE20120791A1 (es) Composiciones y metodos para terapia prolongada con aminopiridinas
BR112012016543A2 (pt) Tratamento com vb-201
NZ734152A (en) Compounds, compositions and methods useful for cholesterol mobilisation
TN2015000135A1 (en) Modified release formulations for oprozomib
CY1121973T1 (el) Θεραπεια φαρμακευτικα ανθεκτικου καρκινου η οποια στοχευει καρκινικα βλαστοκυτταρα
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
PH12014500399A1 (en) Benzothiazolone compound
AR083095A1 (es) Cocristal de aprepitant l-prolina y composicion farmaceutica
EP2611799A4 (en) PHARMACEUTICAL COMPOSITIONS OF LINEZOLID
IN2014MN01806A (es)
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
PE20130308A1 (es) Metodos para tratar infecciones bacterianas recurrentes
MX2014014816A (es) Composicion farmaceutica para tratar inflamacion y dolor.
PH12013501896A1 (en) Use of a sprayable composition comprising ambroxol
MX368641B (es) Compuestos para el tratamiento de inflamación y dolor.
PT2505195E (pt) Composições farmacêuticas tópicas de cetoprofeno e metilsulfonilmetano
PH12015502560B1 (en) Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease

Legal Events

Date Code Title Description
FC Refusal